Acquisition Announced

Eli Lilly and Company acquisition of CrossBridge Bio

US$300m consideration

Announced 14 Apr 2026

Advisers

Target
CrossBridge Bio
Acquirer
Eli Lilly and Company
Target based in
United States (unverified)
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.